Principal Infrastructure Engineer Lead

Genesis Therapeutics is building a world-class computational team to solve problems in drug discovery through machine learning, biophysical simulation, and computational chemistry. We are looking for a Principal Infrastructure Engineer that is excited to help develop new medicines and play a critical role in building out our AI platform.

You Will

• Lead and manage our infrastructure team to maintain and grow our multi-cloud compute infrastructure that supports our ML model training, computational chemistry research, and ongoing drug discovery efforts
• Build out our configuration and procedures for monitoring, resource allocation, and deployment automation, as we continue to grow our autoscaling compute clusters to handle larger workloads
• Work on improvements to our internal job scheduling system to increase our execution throughput, reliability, and compute utilization across heterogeneous pipelines

You Are

• 5+ years of experience building and maintaining cloud infrastructure at scale, e.g. within AWS or GCP
• Proficient with Python, Bash, Terraform, and Kubernetes
• Ideally, experience building and maintaining compute clusters running distributed ML training jobs with 1,000+ GPUs
• Nice to have: hands-on experience with physical hardware + datacenter management

What We Offer

• The opportunity to work on high impact infrastructure that is used to accelerate the discovery of new medicines
• A world-class, tight-knit team of good-hearted people across software, machine learning, computational chemistry, medicinal chemistry, and biology
• Competitive salary and equity. Medical, dental, and vision insurance, and a 401(k) program

Genesis Therapeutics is unifying AI and biotech to discover novel and breakthrough treatments for patients with severe and devastating conditions. Genesis was founded on groundbreaking molecular ML research and since has established itself as the industry leader in AI for small molecule drug discovery. Our team of accomplished biotech leaders and expert drug hunters joins forces with deep learning researchers and software engineers who are pioneering predictive and generative AI technologies for molecules.
Our team has created the industry's most advanced molecular AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule drug discovery and to enable the discovery of novel first-in-class and best-in-class small molecule drugs for challenging and/or undruggable targets. 
The company has leveraged GEMS to build an internal pipeline with multiple programs against high-value targets, including data-poor and canonically undruggable targets where GEMS is uniquely advantaged. In addition, Genesis has two AI platform collaborations across a range of therapeutic areas: Eli Lilly (signed in 2022, with a $20M upfront payment and a $670M total deal size), and Genentech (signed in 2020). We raised a $200M series B in August 2023, and have raised over $280M in funding from top technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures. 
Genesis is headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego. We are proud to be an inclusive workplace and an Equal Opportunity Employer.